Alnylam Pharmaceuticals Stock
Alnylam Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Yvonne L. Greenstreet
- Employees
- 2,500
- Market cap
- $31 B
- IPO
- 01/06/2004
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Cambridge, US, primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Founded in 2002, the company is listed on the NASDAQ and…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Alnylam Pharmaceuticals stock: price history
1D
-0.9%
1W
-0.4%
1M
-3.1%
6M
-25.1%
YTD
-41.7%
1Y
-51.8%
2Y
-22.9%
5Y
+11.2%
10Y
+556.4%
Next earnings date
Next earnings date
29/10/2026 (in 12 days)
Volatility around earnings
~24% stronger price swings than usual
Ask the agents about Alnylam Pharmaceuticals
Analyst assessment of Alnylam Pharmaceuticals
PRICE TARGET LOW
US$253.00
CONSENSUS
US$347.23
MEDIAN
US$345.00
PRICE TARGET HIGH
US$455.00
1
STRONG BUY
38
BUY
12
HOLD
1
SELL
0
STRONG SELL
52
TOTAL · Buy
As of: 14/10/2026
Alnylam Pharmaceuticals stock metrics
P/E
38
P/B
22.81
EV/EBITDA
26.57
RETURN ON EQUITY
12.1%
NET MARGIN
12.7%
DEBT/EQUITY
0.94
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
99.6%
FLOAT SHARES
133,224,372
AVG. DAILY VOLUME (30D)
1,337,969
Insider transactions (SEC)
SUPRAN BRYAN
Greenstreet Yvonne
PYOTT DAVID E I
PYOTT DAVID E I
PYOTT DAVID E I
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -0.9%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Alnylam Pharmaceuticals stock
What does Alnylam Pharmaceuticals do?
Alnylam Pharmaceuticals, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Yvonne L. Greenstreet, the company employs around 2,500 people.
The IPO was on 01/06/2004; the stock trades on NASDAQ under the ticker ALNY.
What do analysts say about Alnylam Pharmaceuticals stock?
52 analysts rate the stock, the consensus is Buy (as of 14/10/2026).
The average price target is US$347.23, ranging from US$253.00 to US$455.00, with a median of US$345.00.
This is an external assessment, not a statement by Market Jury.
When does Alnylam Pharmaceuticals report next?
The next earnings date is 29/10/2026.
Around past earnings, price swings were roughly 24% stronger than usual.
Does Alnylam Pharmaceuticals pay a dividend?
No, Alnylam Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Alnylam Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Alnylam Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Alnylam Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.